



**PATENT**

Attorney Docket No.: 34728/US/2 (470298-00164)  
Applicant File No.: BMED-004/01US

**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

*In re* application of:

MORAN

Serial No. 10/004,118

Filing Date: October 30, 2001

For: *Method for Short-Term and Long-Term Drug Dosimetry*

Examiner: ANDRES, Janet L.

Art Unit: 1646

"EXPRESS MAIL" LABEL NO.:  
EV 529551710 US

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicant wishes to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1273 Off. Gaz. Pat. Office 163, 10/19/2004, no copies of U.S. patents and U.S. published applications are enclosed. Copies of all other references are enclosed.

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.


Serial No. 10/004,118  
Filing Date: October 30, 2001

As far as is known to the undersigned, this Information Disclosure Statement is being filed with the Request for Continued Examination under § 1.114, and is therefore before the mailing of a first office action following a Request for Continued Examination under § 1.114. As such, no fee is required. While no further fee is believed to be due, if this belief is in error the Commissioner is authorized to charge any additional fees, including extension fees or other relief which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our File No. 470298-00164; Our Docket No. 34728/US/2).

Respectfully submitted,

DORSEY & WHITNEY LLP

By:

  
Gurjeey K. Sachdeva, Reg. No. 37,434

Dated: June 15, 2005  
**Customer Number: 32940**  
Dorsey & Whitney LLP  
Four Embarcadero Center, Suite 3400  
San Francisco, CA 94111-4187  
Telephone: (415) 781-1989  
Facsimile: (415) 398-3249

Attachments : Form PTO/SB/8A, Substitute for form 1449  
4 cited references



Substitute for form 1449A/PTO (Modified)				<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	<b>10/004,118</b>	
				Filing Date	<b>October 30, 2001</b>	
				First Named Inventor	<b>MORAN, S. Mark</b>	
				Art Unit	<b>1646</b>	
				Examiner Name	<b>ANDRES, Janet L.</b>	
Sheet	<b>1</b>	of	<b>1</b>	Attorney Docket Number		<b>34728/US/2 (470298-00164)</b>

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A1		4,675,184	06-23-1987	Hasegawa et al.	
A2		4,885,166	12-05-1989	Meyer et al.	
A3		4,917,887	04-17-1990	Hauptmann et al.	
A4		5,019,382	05-28-1991	Cummins, Jr.	
A5		5,605,688	02-25-1997	Himmler et al.	
A6		5,674,942	10-14-1997	Testa et al.	
A7		5,738,845	04-14-1998	Imakawa	
A8		5,906,816	05-25-1999	Soos et al.	
A9		5,939,286	08-17-1999	Johnson et al.	
A10		5,942,223	08-24-1999	Bazer et al.	
A11		6,007,805	12-28-1999	Foster et al.	
A12		6,060,450	05-09-2000	Soos et al.	
A13		6,069,133	05-30-2000	Carlo et al.	
A14		6,472,512 B1	10-29-2002	LaFleur et al.	
A15		6,833,256 B1	12-21-2004	Pontzer et al.	
A16		2004/0225113 A1	11-11-2004	LaFleur et al.	

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
B1		WO 93/08832 A1	05-13-1993	Dallas Biotherapeutics, Inc.	
B2		WO 00/39280 A2/A3	07-06-2000	Viragen, Inc.	
B3		WO 00/40273 A2/A3	07-13-2000	Vical Inc.	

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
C1		SHIRATORI, Y., et al., "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy," <i>Ann. Int. Med.</i> 132(7):517-524 (Apr. 2000).			

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2